To assess and compare the effectiveness and safety of olopatadine 0.7 percent and alcatadine 0.25 percent in patients with allergic conjunctivitis.

A comparative study of the efficacy and safety of olopatadine 0.7% versus alcaftadine 0.25% in allergic conjunctivitis - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/05/067217

Enrollment

Registered

2024-05-13

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H108- Other conjunctivitis

Interventions

Intervention1: Olopatadine 0.7 percent eye drops: Olopatadine 0.7 percent eye drops once daily for 4 weeks. The enrolled patients will be assessed using Clinical grading and Total Ocular Scoring Syste

Eligibility

Inclusion criteria

Inclusion criteria: -Positive medical history of mild to moderate ocular allergies. -Best corrected visual acuity of 6 by 12 or better in each eye. -Absence of contact lens use for a minimum of three days before and throughout the study period. -Willingness to provide informed consent

Exclusion criteria

Exclusion criteria: -Diagnosis of persistent dry eye syndrome. -Use of any topical eye drops, including ocular lubricants, aside from the investigational drugs within the past seventy two hours, or utilization of any experimental medications or devices within the last thirty days. -Taking aspirin, or related products, systemic steroids or H1antihistamines within seven days prior to enrolment. -Presence of an active ocular infection. -Planned surgical procedures during the study period or recent ocular surgical intervention within three months. -Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
Change in Clinical grading and Total Ocular Scoring System TOSS at 7th ,14th and 28th day from baseline in patients with allergic conjunctivitis. Timepoint: Change in Clinical grading and Total Ocular Scoring System TOSS at 7th ,14th and 28th day from baseline in patients with allergic conjunctivitis.	—

Secondary

Measure	Time frame
-Alteration in the Eye Allergy Patient Impact Questionnaire EAPIQ score 28th day from baseline in patients with allergic conjunctivitis -Safety assessment by adverse drug monitoring performa for both the treatment groups at 7th, 14th and 28th day.Timepoint: -Alteration in the Eye Allergy Patient Impact Questionnaire EAPIQ score 28th day from baseline in patients with allergic conjunctivitis -Safety assessment by adverse drug monitoring performa for both the treatment groups at 7th, 14th and 28th day.	—

Measure

Time frame

-Alteration in the Eye Allergy Patient Impact Questionnaire EAPIQ score 28th day from baseline in patients with allergic conjunctivitis -Safety assessment by adverse drug monitoring performa for both the treatment groups at 7th, 14th and 28th day.Timepoint: -Alteration in the Eye Allergy Patient Impact Questionnaire EAPIQ score 28th day from baseline in patients with allergic conjunctivitis -Safety assessment by adverse drug monitoring performa for both the treatment groups at 7th, 14th and 28th day.

—

Countries

India

Contacts

Public ContactDr Garima Sharma

Pt B.D. Sharma PGIMS Rohtak

garima8901308707@gmail.com9053197130

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026